pharmalittle

Pharmalot Andrew Joseph and Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Trump drug pricing flaw, a Gilead deal, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Iran war’s impact on pharma supply chain, a Pfizer Lyme vaccine, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about TrumpRx expectations, a high-dose version of Wegovy, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Lilly weight loss trial, TrumpRx shortcomings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about TrumpRx prices, a J&J psoriasis pill, and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Trump’s drug pricing moves, a GSK asthma drug, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about obesity pill trial results, cholesterol guidelines, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalot: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about TrumpRx shortcomings, Lilly targeting employers, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Moderna’s $2.25 billion settlement, FDA warning letters, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the FDA pushing OTC meds, its new trial standards, and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA reversal on a Moderna vaccine, the U.K. life sciences sector, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly bulking up on weight-loss drugs, scrutiny of a 340B contractor, and more